Company Encyclopedia
View More
name
Tela Bio
TELA.US
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
330.79 B
TELA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking27/42
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE1654.21%A
    • Profit Margin-50.61%E
    • Gross Margin67.98%A
  • Growth ScoreB
    • Revenue YoY12.24%B
    • Net Profit YoY6.08%C
    • Total Assets YoY16.17%A
    • Net Assets YoY124.82%A
  • Cash ScoreC
    • Cash Flow Margin-197.59%D
    • OCF YoY12.24%B
  • Operating ScoreA
    • Turnover1.34A
  • Debt ScoreE
    • Gearing Ratio97.47%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TELA Bio Inc. to Present at Piper Sandler 37th Annual Healthcare Conference

    TELA Bio Inc., a medical technology company, will present at Piper Sandler's 37th Annual Healthcare Conference on December 3, 2025. The presentation is scheduled for 2:30 pm ET and will be available via live and archived webcast at ir.telabio.com. This announcement was originally published by TELA Bio Inc. via GlobeNewswire.

    Reuters·
    US
    TELA
    -0.87%
    Reuters·
    US
    TELA
    -0.87%

    Strategic Initiatives and Financial Adjustments Underpin Buy Rating for TELA Bio Despite Short-term Challenges

    Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on TELA Bio with a $4.00 price target, citing strategic initiatives and financial adjustments. Despite missing Q3 revenue expectations and lowering full-year guidance, TELA Bio is confident in its commercial strategy. The company has hired experienced leaders, raised $13 million in equity, and increased debt capacity to support growth. Citizens JMP also maintained a Buy rating with a $5.00 price target.

    Tip Ranks·
    US
    TELA
    -0.87%
    Tip Ranks·
    US
    TELA
    -0.87%

    EW Healthcare Partners Fund 2 Acquires Common Shares of TELA Bio Inc

    EW Healthcare Partners Fund 2, L.P. and other beneficial owners have acquired common shares of TELA Bio Inc. The acquisition details were published via EDGAR by TELA Bio Inc. on November 17, 2025.

    Reuters·
    US
    TELA
    -0.87%
    Reuters·
    US
    TELA
    -0.87%

    TELA Bio Grants Stock Options and Restricted Units to New Employees

    TELA Bio Inc. has approved inducement grants for new employees, including restricted stock units for 17 hires covering 30,200 shares, vesting over four years. Additionally, one employee received an option to purchase 25,000 shares at $1.19 per share, vesting over four years. The grant date is November 10, 2025. This announcement was made via GlobeNewswire on November 17, 2025.

    Reuters·
    US
    TELA
    -0.87%
    Reuters·
    US
    TELA
    -0.87%

    TELA Bio Secures $70 Million Term Loan Facility from Perceptive Credit Holdings

    TELA Bio Inc. has secured a $70 million term loan facility from Perceptive Credit Holdings V, LP. The facility includes an initial $60 million loan to be funded on November 14, 2025, and an additional $10 million loan subject to conditions. The loan matures on November 14, 2030, with an interest rate of 7.85% plus the greater of the Reference Rate or 4.25%. TELA Bio will issue warrants to purchase up to 2,000,000 shares of common stock at $1.11. The facility is secured by a first lien on TELA Bio’s assets.

    Reuters·
    US
    TELA
    -0.87%
    Reuters·
    US
    TELA
    -0.87%
    © 2025 Longbridge｜Disclaimer